Publications by authors named "Vivianne Oyefusi"
Article Synopsis
- Neoadjuvant chemotherapy (NAT) is used for pancreatic adenocarcinoma (PDAC), but many patients experience early recurrence post-surgery, which may cancel out the benefits of the treatment.
- A study analyzed 273 PDAC patients who underwent pancreaticoduodenectomy after NAT, finding that 23% had early recurrence, with the median time to recurrence being just 4 months for this group compared to 16 months for those with later recurrence.
- Key indicators for early recurrence included higher pre- and post-treatment tumor markers (Ca19-9 levels) and a greater positive lymph node ratio; however, receiving adjuvant chemotherapy was linked to a lower risk of early recurrence, highlighting the need for better individualized treatment strategies
Purpose Of Review: Disturbed sleep may be a mechanism of race differences in nocturnal blood pressure non-dipping. In support of this proposal, we summarize recent research from three literatures: (1) race differences (Black compared with White individuals) in nocturnal blood pressure non-dipping, (2) the association between disturbed sleep and nocturnal blood pressure non-dipping, and (3) race differences in disturbed sleep.
Recent Findings: Black individuals are nearly twice as likely to have blood pressure non-dipping profiles compared with White individuals.